About Arcellx Inc
Ticker
info
ACLX
Trading on
info
NASDAQ
ISIN
info
US03940C1009
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Rami Elghandour
Headquarters
info
800 Bridge Parkway, Redwood City, CA, United States, 94065
Employees
info
163
Website
info
arcellx.com
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; ARC-SparX programs in Phase 1 trials; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Metrics
BasicAdvanced
Market cap
info
$3.6B
P/E ratio
info
-
EPS
info
-$2.99
Dividend Yield
info
0.00%
Beta
info
0.28
Forward P/E ratio
info
0
EBIDTA
info
$-185M
Ex dividend date
info
-
Price & volume
Market cap
info
$3.6B
Average daily volume
info
0.6M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
46.89
Price to book
info
8.64
Earnings
EPS
info
-$2.99
EPS estimate (current quarter)
info
-$0.74
EPS estimate (next quarter)
info
-$0.77
EBITDA
info
$-185M
Revenues (TTM)
info
$76.8M
Revenues per share (TTM)
info
$1.42
Technicals
Beta
info
0.28
52-week High
info
$107.37
52-week Low
info
$47.86
50-day moving average
info
$62.76
200-day moving average
info
$73.00
Short ratio
info
8.07
Short %
info
15.74%
Management effectiveness
ROE (TTM)
info
-35.56%
ROA (TTM)
info
-16.69%
Profit margin
info
-211.46%
Gross profit margin
info
$-98.8M
Operating margin
info
-847.56%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
-79.30%
Share stats
Outstanding Shares
info
55.1M
Float
info
32.7M
Insiders %
info
14.50%
Institutions %
info
102.08%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 18 analysts.

Average price target

info
$111.13
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.51
-$0.50
-1.96%
Q2 • 24Missed
-$0.48
-$0.24
-96.16%
Q3 • 24Missed
-$0.87
-$0.47
-83.39%
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$15.3M
$-47.1M
-308.40%
Q4 • 24
$8.1M
$-62.3M
-766.02%
Q1 • 25
-46.75%
32.26%
148.38%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$711M
$257M
36.06%
Q4 • 24
$648M
$231M
35.67%
Q1 • 25
-8.89%
-9.89%
-1.09%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-46M
$-4.1M
$-6M
$-47.5M
Q4 • 24
$-63.1M
$37.8M
$0.5M
$-63.9M
Q1 • 25
37.18%
-1,017.09%
-109.02%
34.50%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Arcellx Inc share?
Collapse

Arcellx Inc shares are currently traded for undefined per share.

How many shares does Arcellx Inc have?
Collapse

Arcellx Inc currently has 55.1M shares.

Does Arcellx Inc pay dividends?
Collapse

No, Arcellx Inc doesn't pay dividends.

What is Arcellx Inc 52 week high?
Collapse

Arcellx Inc 52 week high is $107.37.

What is Arcellx Inc 52 week low?
Collapse

Arcellx Inc 52 week low is $47.86.

What is the 200-day moving average of Arcellx Inc?
Collapse

Arcellx Inc 200-day moving average is $73.00.

Who is Arcellx Inc CEO?
Collapse

The CEO of Arcellx Inc is Rami Elghandour.

How many employees Arcellx Inc has?
Collapse

Arcellx Inc has 163 employees.

What is the market cap of Arcellx Inc?
Collapse

The market cap of Arcellx Inc is $3.6B.

What is the P/E of Arcellx Inc?
Collapse

The current P/E of Arcellx Inc is null.

What is the EPS of Arcellx Inc?
Collapse

The EPS of Arcellx Inc is -$2.99.

What is the PEG Ratio of Arcellx Inc?
Collapse

The PEG Ratio of Arcellx Inc is null.

What do analysts say about Arcellx Inc?
Collapse

According to the analysts Arcellx Inc is considered a buy.